MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, has announced it will release its financial results for the second quarter and first half of 2024 on August 21, 2024, after market close. The company will host a conference call with live Q&A at 4:30pm ET / 22:30 CET on the same day.
Key participants in the call will include Michael K. McGarrity, Chief Executive Officer, and Ron Kalfus, Chief Financial Officer. The conference call will be accessible via various dial-in numbers for different countries and a webcast link. A replay of the webcast will be available on the company's website following the live call.
MDxHealth SA (NASDAQ: MDXH), un'azienda di diagnostica di precisione in fase commerciale, ha annunciato che rilascerà i suoi risultati finanziari per il secondo trimestre e il primo semestre del 2024 il 21 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call con sessione di domande e risposte in diretta alle 16:30 ET / 22:30 CET dello stesso giorno.
I principali partecipanti alla call includeranno Michael K. McGarrity, Amministratore Delegato, e Ron Kalfus, Direttore Finanziario. La conference call sarà accessibile tramite vari numeri per il dial-in per diversi paesi e un link per la webcasting. Una registrazione della webcasting sarà disponibile sul sito web dell'azienda dopo la call dal vivo.
MDxHealth SA (NASDAQ: MDXH), una empresa de diagnóstico de precisión en fase comercial, ha anunciado que publicará sus resultados financieros para el segundo trimestre y la primera mitad de 2024 el 21 de agosto de 2024, después del cierre del mercado. La empresa organizará una llamada de conferencia con sesión de preguntas y respuestas en vivo a las 4:30 pm ET / 22:30 CET del mismo día.
Los participantes clave en la llamada incluirán a Michael K. McGarrity, Director Ejecutivo, y Ron Kalfus, Director Financiero. La llamada de conferencia será accesible a través de varios números de marcación para diferentes países y un enlace de webcast. Una repetición de la transmisión web estará disponible en el sitio web de la empresa después de la llamada en vivo.
MDxHealth SA (NASDAQ: MDXH)는 상업 단계의 정밀 진단 회사로서 2024년 두 번째 분기 및 상반기 재무 결과를 2024년 8월 21일, 마감 후 발표한다고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET / 10시 30분 CET에 라이브 Q&A가 포함된 전화 회의를 개최할 예정입니다.
회의의 주요 참가자는 Michael K. McGarrity CEO와 Ron Kalfus CFO가 포함됩니다. 전화 회의는 다양한 국가에 대한 여러 다이얼인 번호와 웹 캐스트 링크를 통해 접근할 수 있습니다. 라이브 호출 후 회사 웹사이트에서 웹캐스트의 재생이 가능합니다.
MDxHealth SA (NASDAQ: MDXH), une entreprise de diagnostics de précision en phase commerciale, a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre et le premier semestre de 2024 le 21 août 2024, après la fermeture du marché. L'entreprise organisera une conférence téléphonique avec une séance de questions-réponses en direct à 16h30 ET / 22h30 CET le même jour.
Les principaux participants à l'appel comprendront Michael K. McGarrity, Directeur Général, et Ron Kalfus, Directeur Financier. La conférence téléphonique sera accessible via plusieurs numéros d'appel pour différents pays et un lien de webinaire. Un enregistrement du webinaire sera disponible sur le site web de l'entreprise après l'appel en direct.
MDxHealth SA (NASDAQ: MDXH), ein Unternehmen für präzise Diagnosetechnologie in der kommerziellen Phase, hat angekündigt, seine finanziellen Ergebnisse für das zweite Quartal und das erste Halbjahr 2024 am 21. August 2024 nach Börsenschluss zu veröffentlichen. Das Unternehmen wird am selben Tag um 16:30 Uhr ET / 22:30 Uhr CET eine Telefonkonferenz mit Live-Q&A veranstalten.
Zu den Hauptteilnehmern des Anrufs gehören Michael K. McGarrity, Chief Executive Officer, und Ron Kalfus, Chief Financial Officer. Die Telefonkonferenz wird über verschiedene Einwahlnummern für verschiedene Länder und einen Webcast-Link zugänglich sein. Eine Wiederholung des Webcasts wird nach dem Live-Anruf auf der Website des Unternehmens verfügbar sein.
- None.
- None.
MDxHealth to Present Second Quarter and First Half 2024 Financial Results
and Corporate Update on August 21
Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET
IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and six-month period ended June 30, 2024, after market close on Wednesday, August 21, 2024.
| Title: | MDxHealth Presents Second Quarter and First Half 2024 Financial Results and Corporate Update Conference Call and Webcast |
| Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
| Date: | August 21, 2024 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call Dial-in Details: | United States: 1-877-407-9716 Belgium: 0800 73 566 The Netherlands: 0800 022 3580 United Kingdom: 0 800 756 3429 |
| Conference ID: | 13747618 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1679031&tp_key=41436200eb |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About MDxHealth
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
| MDxHealth info@mdxhealth.com | |
| LifeSci Advisors (IR & PR) US: +1 949 271 9223 ir@mdxhealth.com |
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.
FAQ
When will MDxHealth (MDXH) release its Q2 and H1 2024 financial results?
What time is MDxHealth's (MDXH) Q2 2024 earnings call scheduled for?
Who will be speaking at MDxHealth's (MDXH) Q2 2024 earnings call?
How can I access MDxHealth's (MDXH) Q2 2024 earnings call?
